ArticleJournal for immunotherapy of cancer2024

Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.

Vania Lo Presti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.